THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY published 11 principles and detailed guidance to the Centers for Medicare & Medicaid Services as it implements the Merit-based Incentive Payment System and Alternative Payment Models under the Medicare Access and CHIP Reauthorization on Act of 2015, which replaced the Sustainable Growth Rate formula.
On Oct. 19, FDA granted an accelerated approval to dostarlimab-gxly (Jemperli) for the treatment of patients with previously untreated stage 2 or stage 3 rectal cancer that is mismatch repair deficient or microsatellite instability–high, as determined by an FDA-authorized test.
